Figure 1 (Daxxify 01)
Daxxify Injection, Powder, Lyophilized, For Solution
Product Images NDC 72960-112
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Daxxify (NDC 72960-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Revance Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Study GL-1)
Figure 2 (Study GL-2)
This text seems to be a table or a section of a scientific study report. It shows some numerical data that represents the percentage of subjects or patients that are grouped in some categories. It also includes some information on "Study GL-2". Without further context, it is not clear what this data represents or what the categories mean.*
Principal Display Panel (1.2 mL Vial Carton)
This is a description of a pharmaceutical product named "DAXXIFY". It is a type of botulinum toxin, and the only available information seems to be related to dosage and storage. The product comes in single-dose vials and should be discarded if unused. Dosage instructions should be followed carefully. The text warns against using dosing units from different commercial products. There are no preservatives in the product, and it should be kept away from children and stored at room temperature or refrigerated before use. The product must be used within 72 hours after reconstitution and should not be frozen. "DAXXIFY" is a trademark of REVANCE Therapeutics, Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
